Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Tanner, E, Puechl, A, Levinson, K, Havrilesky, LJ, Sinno, A, Secord, AA, Fader, AN, and Lee, PS. "Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer." Gynecologic oncology 147, no. 3 (December 2017): 535-540.

Full Text

Gamble, C, Havrilesky, LJ, Myers, ER, Chino, JP, Hollenbeck, S, Plichta, JK, Kelly Marcom, P, Shelley Hwang, E, Kauff, ND, and Greenup, RA. "Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer." Annals of surgical oncology 24, no. 11 (October 2017): 3116-3123.

Full Text

Phippen, NT, Secord, AA, Wolf, S, Samsa, G, Davidson, B, Abernethy, AP, Cella, D, Havrilesky, LJ, Burger, RA, Monk, BJ, and Leath, CA. "Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study." Gynecologic oncology 147, no. 1 (October 2017): 98-103.

Full Text

Bateman, NW, Dubil, EA, Wang, G, Hood, BL, Oliver, JM, Litzi, TA, Gist, GD, Mitchell, DA, Blanton, B, Phippen, NT, Tian, C, Zahn, CM, Cohn, DE, Havrilesky, LJ, Berchuck, A, Shriver, CD, Darcy, KM, Hamilton, CA, Conrads, TP, and Maxwell, GL. "Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients." Cancer 123, no. 20 (October 2017): 4004-4012.

Full Text

Moss, HA, Havrilesky, LJ, and Chino, J. "Insurance coverage among women diagnosed with a gynecologic malignancy before and after implementation of the Affordable Care Act." Gynecologic oncology 146, no. 3 (September 2017): 457-464.

Full Text

Fountain, CR, and Havrilesky, LJ. "Promoting Same-Day Discharge for Gynecologic Oncology Patients in Minimally Invasive Hysterectomy." Journal of minimally invasive gynecology 24, no. 6 (September 2017): 932-939.

Full Text

Havrilesky, LJ. "The costs of adding laparoscopy to the management of advanced stage epithelial ovarian cancer." Gynecologic oncology 146, no. 3 (September 2017): 441-442.

Full Text

Dilley, SE, Havrilesky, LJ, Bakkum-Gamez, J, Cohn, DE, Michael Straughn, J, Caughey, AB, and Rodriguez, MI. "Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention." Gynecologic oncology 146, no. 2 (August 2017): 373-379.

Full Text

Havrilesky, LJ, Moss, HA, Chino, J, Myers, ER, and Kauff, ND. "Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers." Gynecologic oncology 145, no. 3 (June 2017): 549-554.

Full Text

Wenzel, L, Mukamel, D, Osann, K, Havrilesky, L, Sparks, L, Lipscomb, J, Wright, AA, Walker, J, Alvarez, R, Van Le, L, Robison, K, Bristow, R, Morgan, R, Rimel, BJ, Ladd, H, Hsieh, S, Wahi, A, and Cohn, D. "Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients." Contemporary clinical trials 57 (June 2017): 29-36.

Full Text

Pages